Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Gross Profit (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Gross Profit for 14 consecutive years, with $146.8 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 33.09% to $146.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $542.1 million through Dec 2025, up 48.85% year-over-year, with the annual reading at $542.1 million for FY2025, 48.85% up from the prior year.
  • Gross Profit hit $146.8 million in Q4 2025 for Ani Pharmaceuticals, up from $134.4 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $146.8 million in Q4 2025 to a low of -$8.8 million in Q1 2021.
  • Historically, Gross Profit has averaged $73.1 million across 5 years, with a median of $76.2 million in 2023.
  • Biggest five-year swings in Gross Profit: plummeted 131.41% in 2021 and later skyrocketed 443.84% in 2022.
  • Year by year, Gross Profit stood at $27.0 million in 2021, then soared by 114.22% to $57.9 million in 2022, then soared by 35.11% to $78.2 million in 2023, then skyrocketed by 40.98% to $110.3 million in 2024, then soared by 33.09% to $146.8 million in 2025.
  • Business Quant data shows Gross Profit for ANIP at $146.8 million in Q4 2025, $134.4 million in Q3 2025, and $136.8 million in Q2 2025.